Clinical relevance of understanding mitogen-activated protein kinases involved in asthma

References

• Khalaf K, Paoletti G, Puggioni F, et al. Asthma from immune pathogenesis to precision medicine. Semin Immunol. 2019;46:101294.
   PubMed Web of Science ®Google Scholar
• Lambrecht BN, Hammad H, Fahy JV. The cytokines of asthma. Immunity. 2019;50:975–991.
   PubMed Web of Science ®Google Scholar
• Holgate ST, Wenzel S, Postma DS, et al. Asthma. Nat Rev Dis Primers. 2015;1:15025.
   PubMed Web of Science ®Google Scholar
• Papi A, Brightling C, Pedersen SE, et al. Asthma. Lancet. 2018;391:783–800.
   PubMed Web of Science ®Google Scholar
• Pelaia G, Cuda G, Vatrella A, et al. Mitogen-activated protein kinases and asthma. J Cell Physiol. 2005;202:642.653.
   Web of Science ®Google Scholar
• Chung KF. p38 mitogen-activated protein kinase pathways in asthma and COPD. Chest. 2011;139:1470–1479.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Kinases as novel therapeutic targets in asthma and chronic obstructive pulmonary disease. Pharmacol Rev. 2016;68:788–815.
   PubMed Web of Science ®Google Scholar
• Khorasanizadeh M, Eskian M, Gelfand EW, et al. Mitogen-activated protein kinases as therapeutic targets for asthma. Pharmacol Ther. 2017;174:112–126.
   PubMed Web of Science ®Google Scholar
• Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 2002;298:1911–1912.
   PubMed Web of Science ®Google Scholar
• Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature. 2001;410:37–40.
   PubMed Web of Science ®Google Scholar
• Pelaia G, Vatrella A, Busceti MT, et al. Cellular mechanisms underlying eosinophilic and neutrophilic airway inflammation in asthma. Mediators Inflamm. 2015:879783.
   PubMed Web of Science ®Google Scholar
• Kannan Y, Wilson MS. TEC and MAPK kinase signalling pathways in T helper (TH) differentiation and allergic asthma. J Clin Cell Immunol. 2012;Suppl 12:11.
   PubMedGoogle Scholar
• Kabata H, Moro K, Koyashu S. The group 2 innate lymphoid cell (ILC2) regulatory network and its underlying mechanisms. Immunol Rev. 2018;286:37–52.
   PubMed Web of Science ®Google Scholar
• Pelaia C, Paoletti G, Puggioni F, et al. Interleukin-5 in the pathophysiology of severe asthma. Front Physiol. 2019;10:1514.
   PubMed Web of Science ®Google Scholar
• Zheng H, Zhang X, Castillo EF, et al. Leptin enhances TH2 and ILC2 responses in allergic airway disease. J Biol Chem. 2016;291:22043–22052.
   PubMed Web of Science ®Google Scholar
• Monin L, Gaffen SL. Interleukin 17 family cytokines: signaling mechanisms, biological activities, and therapeutic implications. Cold Spring Harb Perspect Biol. 2018;10:pii:a028522.
   PubMed Web of Science ®Google Scholar
• Al-Ramli W, Prefontaine D, Chouiali F, et al. TH17-associated cytokines (IL-17A and IL-17F) in severe asthma. J Allergy Clin Immunol. 2009;123:1185–1187.
   PubMed Web of Science ®Google Scholar
• Lee JC, Laydon JT, McDonnell PC, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature. 1994;372:739–746.
   PubMed Web of Science ®Google Scholar
• Underwood DC, Osborn RR, Kotzer CJ, et al. SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. J Pharmacol Exp Ther. 2000;293:281–288.
   PubMed Web of Science ®Google Scholar
• O’Neil JD, Ammit AJ, Clark AR. MAPK p38 regulates inflammatory gene expression via tristetraprolin: doing good by stealth. Int J Biochem Cell Biol. 2018;94:6–9.
   PubMed Web of Science ®Google Scholar
• Winzen R, Kracht M, Ritter B, et al. The p38 MAP kinase pathway signals for cytokine-induced mRNA stabilization via MAP kinase-activated protein kinase 2 and an AU-rich region-targeted mechanism. Embo J. 1999;18:4969–4980.
   PubMed Web of Science ®Google Scholar
• Skapenko A, Lipsky PE, Kraetsch HG, et al. Antigen-independent Th2 cell differentiation by stimulation of CD28: regulation via IL-4 gene expression and mitogen-activated protein kinase activation. J Immunol. 2001;166:4283–4292.
   PubMed Web of Science ®Google Scholar
• Kuruvilla ME, Lee FE, Lee GB. Understanding asthma phenotypes, endotypes, and mechanisms of disease. Clin Rev Allergy Immunol. 2019;56:219–233.
   PubMed Web of Science ®Google Scholar
• Chen C-H, Zhang D-H, LaPorte JM, et al. Cyclic AMP activates p38 mitogen-activated protein kinase in Th2 cells: phosphorylation of GATA-3 and stimulation of Th2 cytokine gene expression. J Immunol. 2000;165:5597–5605.
   PubMed Web of Science ®Google Scholar
• Maneechotesuwan K, Xin Y, Ito K, et al. Regulation of Th2 cytokine genes by p38 MAPK-mediated phosphorylation of GATA-3. J Immunol. 2007;178:2491–2498.
   PubMed Web of Science ®Google Scholar
• Kankaanranta H, De Souza PM, Barnes PJ, et al. SB203580, an inhibitor of p38 mitogen-activated protein kinase, enhances constitutive apoptosis of cytokine-deprived human eosinophils. J Pharmacol Exp Ther. 1999;290:621–628.
   PubMed Web of Science ®Google Scholar
• Adachi T, Choudhury BK, Stafford S, et al. The differential role of extracellular-signal regulated kinases and p38 mitogen-activated protein kinase in eosinophil functions. J Immunol. 2000;165:2198–2204.
   PubMed Web of Science ®Google Scholar
• Kampen GT, Stafford S, Adachi T, et al. Eotaxin induces degranulation and chemotaxis of eosinophils through the activation of ERK2 and p38 mitogen-activated protein kinases. Blood. 2000;95:1911–1917.
   PubMed Web of Science ®Google Scholar
• Ishizuka T, Okajima F, Ishiwara M, et al. Sensitized mast cells migrate toward the antigen: a response regulated by p38 mitogen-activated protein kinase and Rho-associated coiled-coil-forming protein kinase. J Immunol. 2001;167:2298–2304.
   PubMed Web of Science ®Google Scholar
• Feoktistov I, Goldstein AE, Biaggioni I. Role of p38 mitogen-activated protein kinase and extracellular signal-regulated protein kinase kinase in adenosine A2B receptor-mediated interleukin-8 production in mast cells. Mol Pharmacol. 1999;55:726–734.
   PubMed Web of Science ®Google Scholar
• Tamura DY, Moore EE, Johnson JL, et al. p38 mitogen-activated protein kinase inhibition attenuates intercellular adhesion molecule-1 up-regulation on human pulmonary microvascular endothelial cells. Surgery. 1998;124:403–407.
   PubMed Web of Science ®Google Scholar
• Nick JA, Young SK, Brown KK, et al. Role of p38 mitogen-activated protein kinase in a murine model of pulmonary inflammation. J Immunol. 2000;164:2151–2159.
   PubMed Web of Science ®Google Scholar
• Irusen E, Matthews JG, Takahashi A, et al. p38 mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma. J Allergy Clin Immunol. 2002;109:649–657.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2013;131:636–645.
   PubMed Web of Science ®Google Scholar
• Mercado N, To Y, Kobayashi Y, et al. p38 MAP kinase-γ inhibition by long-acting β2 adrenergic agonists reversed steroid insensitivity in severe asthma. Mol Pharmacol. 2011;80:1128–1135.
   PubMed Web of Science ®Google Scholar
• Southworth T, Mason S, Bell A, et al. PI3K, p38 and JAK/STAT signalling in bronchial tissue from patients with asthma following allergen challenge. Biomarker Res. 2018;6:14.
   PubMed Web of Science ®Google Scholar
• Pelaia G, Cuda G, Vatrella A, et al. Effects of transforming growth factor-β and budesonide on mitogen-activated protein kinase activation and apoptosis in airway epithelial cells. Am J Respir Cell Mol Biol. 2003;29:12–18.
   PubMed Web of Science ®Google Scholar
• Bucchieri F, Puddicombe SM, Lordan JL, et al. Asthmatic bronchial epithelium is more susceptible to oxidant-induced apoptosis. Am J Respir Cell Mol Biol. 2002;27:179–185.
   PubMed Web of Science ®Google Scholar
• Trautmann A, Schmid-Grendelmeier P, Kruger K, et al. T cells and eosinophils cooperate in the induction of bronchial epithelial cell apoptosis in asthma. J Allergy Clin Immunol. 2002;109:329–337.
   PubMed Web of Science ®Google Scholar
• O’Sullivan MP, Tyner JW, Holtzman MJ. Apoptosis in the airways: another balancing act in the epithelial program. Am J Respir Cell Mol Biol. 2003;29:3–7.
   PubMed Web of Science ®Google Scholar
• Vignola AM, Mirabella F, Costanzo G, et al. Airway remodeling in asthma. Chest. 2003;123(3Suppl):417S–422S.
   PubMedGoogle Scholar
• Elias JA, Zhu Z, Chupp G, et al. Airway remodeling in asthma. J Clin Invest. 1999;104:1001–1006.
   PubMed Web of Science ®Google Scholar
• Fitzgerald SM, Lee SA, Hall K, et al. Human lung fibroblasts express IL-6 in response to signaling following mast cell contact. Am J Respir Cell Mol Biol. 2004;30:585–593.
   PubMed Web of Science ®Google Scholar
• Wuits WA, Vanaudenaerde BM, Dupont LJ, et al. N-acetylcysteine reduces chemokine release via inhibition of p38 MAPK in human airway smooth muscle cells. Eur Respir J. 2003;22:43–49.
   PubMed Web of Science ®Google Scholar
• Clark AR. MAP kinase phosphatase 1: a novel mediator of biological effects of glucocorticoids? J Endocrinol. 2003;178:5–12.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Corticosteroid effects on cell signalling. Eur Respir J. 2006;27:413–426.
   PubMed Web of Science ®Google Scholar
• Bhavsar P, Hew M, Khorasani N, et al. Relative corticosteroid insensitivity of alveolar macrophages in severe asthma compared to non-severe asthma. Thorax. 2008;63:784–790.
   PubMed Web of Science ®Google Scholar
• Mercado N, Hakim A, Kobayashi Y, et al. Restoration of corticosteroid sensitivity by p38 mitogen activated protein kinase inhibition in peripheral blood mononuclear cells from severe asthma. PloS One. 2012;7:e41582.
   PubMed Web of Science ®Google Scholar
• Bhavsar P, Khorasani N, Hew M, et al. Effect of p38 MAPK inhibition on corticosteroid suppression of cytokine release in severe asthma. Eur Respir J. 2010;35:750–756.
   PubMed Web of Science ®Google Scholar
• Lea S, Harbron C, Khan N, et al. Corticosteroid insensitive alveolar macrophages from asthma patients; synergistic interaction with a p38 mitogen-activated protein kinase (MAPK) inhibitor. Br J Clin Pharmacol. 2015;79:756–766.
   PubMed Web of Science ®Google Scholar
• Mei D, Tan WSD, Wong WSF. Pharmacological strategies to regain steroid sensitivity in severe asthma and COPD. Curr Opin Pharmacol. 2019;46:73–81.
   PubMed Web of Science ®Google Scholar
• Trifilieff A, Keller TH, Press NJ, et al. CGH2466, a combined adenosine receptor antagonist, p38 mitogen-activated protein kinase and phosphodiesterase type 4 inhibitor with potent in vitro and in vivo anti-inflammatory activities. Br J Pharmacol. 2005;144:1002–1010.
   PubMed Web of Science ®Google Scholar
• Ma JY, Medicherla S, Kerr I, et al. Selective p38α mitogen-activated protein kinase inhibitor attenuates lung inflammation and fibrosis in IL-13 transgenic mouse model of asthma. J Asthma Allergy. 2008;1:31–44.
   PubMedGoogle Scholar
• Duan W, Chan JH, McKay K. Inhaled p38α mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice. Am J Respir Crit Care Med. 2005;171:571–578.
   PubMed Web of Science ®Google Scholar
• Nath P, Leung SY, Williams A. Importance of p38 mitogen-activated protein kinase pathway in allergic airway remodelling and bronchial hyperresponsiveness. Eur J Pharmacol. 2006;544:160–167.
   PubMed Web of Science ®Google Scholar
• Karin M, Zheng-gang L, Zandi E. AP-1 function and regulation. Curr Opin Cell Biol. 1997;9:240–246.
   PubMed Web of Science ®Google Scholar
• Ip YT, Davis RJ. Signal transduction by the c-Jun N-terminal kinase (JNK): from inflammation to development. Curr Opin Cell Biol. 1998;10:205–219.
   PubMed Web of Science ®Google Scholar
• Demoly P, Basset-Seguin N, Chanez P, et al. c-fos proto-oncogene expression in bronchial biopsies of asthmatics. Am J Respir Cell Mol Biol. 1992;7:128–133.
   PubMed Web of Science ®Google Scholar
• Dong C, Yang DD, Wysk M, et al. Defective T cell differentiation in the absence of Jnk1. Science. 1998;282:2092–2095.
   PubMed Web of Science ®Google Scholar
• Jabara HH, Geha RS. Jun N-terminal kinase is essential for CD40-mediated IgE class switching in B cells. J Allergy Clin Immunol. 2005;115:856–863.
   PubMed Web of Science ®Google Scholar
• Kankaanranta H, Ilmarinen P, Zhang X, et al. Tumour necrosis factor-α regulates human eosinophil apoptosis via ligation of TNF-receptor 1 and balance between NFκB and AP-1. PLoS One. 2014;9:e90298.
   PubMed Web of Science ®Google Scholar
• Adcock IM, Lane SJ, Brown CR, et al. Abnormal glucocorticoid receptor-activator protein 1 interaction in steroid-resistant asthma. J Exp Med. 1995;182:1951–1958.
   PubMed Web of Science ®Google Scholar
• Lane SJ, Adcock IM, Richards D, et al. Corticosteroid-resistant bronchial asthma is associated with increased c-fos expression in monocytes and T lymphocytes. J Clin Invest. 1998;102:2156–2164.
   PubMed Web of Science ®Google Scholar
• Kobayashi Y, Mercado N, Miller-Larsson A, et al. Increased corticosteroid sensitivity by a long-acting β2 agonist formoterol via β2 adrenoceptor independent protein phosphatase 2 activation. Pulm Pharmacol Ther. 2012;25:201–207.
   PubMed Web of Science ®Google Scholar
• Papi A, Contoli M, Adcock IM, et al. Rhinovirus infection causes steroid resistance in airway epithelium through nuclear factor κB and c-Jun N-terminal kinase activation. J Allergy Clin Immunol. 2013;132:1075–1085.e6.
   PubMed Web of Science ®Google Scholar
• van der Velden JL, Hoffman SM, Alcorn JF, et al. Absence of c-Jun NH2-terminal kinase 1 protects against house dust mite-induced pulmonary remodeling but not airway hyperresponsiveness and inflammation. Am J Physiol Lung Cell Mol Physiol. 2014;306:L866–875.
   PubMed Web of Science ®Google Scholar
• Hashimoto S, Gon Y, Takeshita I, et al. Transforming growth factor-β1 induces phenotypic modulation of human lung fibroblast to myofibroblast through c-Jun-NH2-terminal kinase-dependent pathway. Am J Respir Crit Care Med. 2001;163:152–157.
   PubMed Web of Science ®Google Scholar
• Hashimoto S, Gon Y, Takeshita I, et al. IL-4 and IL-13 induce myofibroblastic phenotype of human lung fibroblasts through c-Jun-NH2-terminal kinase-dependent pathway. J Allergy Clin Immunol. 2001;107:1001–1008.
   PubMed Web of Science ®Google Scholar
• Lee KY, Ito K, Hayashi R, et al. NF-κB and activator protein 1 response elements and the role of histone modifications in IL-1β-induced TGF-β1 gene transcription. J Immunol. 2006;176:603–615.
   PubMed Web of Science ®Google Scholar
• Xie S, Sukkar MB, Issa R, et al. Mechanisms of induction of airway smooth muscle hyperplasia by transforming growth factor-β. Am J Physiol Lung Cell Mol Physiol. 2007;293:L245–L253.
   PubMed Web of Science ®Google Scholar
• Eynott PR, Nath P, Leung SY, et al. Allergen-induced inflammation and airway epithelial and smooth muscle cell proliferation: role of Jun N-terminal kinase. Br J Pharmacol. 2003;140:1373–1380.
   PubMed Web of Science ®Google Scholar
• Eynott PR, Xu L, Bennett BL, et al. Effect of an inhibitor of Jun N-terminal protein kinase, SP600125, in single allergen challenge in sensitized rats. Immunology. 2004;112:446–453.
   PubMed Web of Science ®Google Scholar
• Nath P, Eynott P, Leung SY, et al. Potential role of c-Jun NH2-terminal kinase in allergic airway inflammation and remodelling: effects of SP600125. Eur J Pharmacol. 2003;506:273–283.
   Web of Science ®Google Scholar
• Wu HM, Fang L, Shen QY, et al. SP600125 promotes resolution of allergic airway inflammation via TLR9 in an OVA-induced murine acute asthma model. Mol Immunol. 2015;67:311–316.
   PubMed Web of Science ®Google Scholar
• Chialda L, Zhang M, Brune K, et al. Inhibitors of mitogen-activated protein kinases differentially regulate costimulated T cell cytokine production and mouse airway eosinophilia. Respir Res. 2005;6:36.
   PubMed Web of Science ®Google Scholar
• English J, Pearson G, Wilsbacher J, et al. New insights into the control of MAP kinase pathways. Exp Cell Res. 1999;253:255–270.
   PubMed Web of Science ®Google Scholar
• Widmann C, Gibson S, Jarpe MB, et al. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol Rev. 1999;79:143–180.
   PubMed Web of Science ®Google Scholar
• McCubrey JA, Stratford May W, Duronio V, et al. Serine/threonine phosphorylation in cytokine signal transduction. Leukemia. 2000;14:9–21.
   PubMed Web of Science ®Google Scholar
• Yamashita M, Kimura M, Kubo M, et al. T cell antigen receptor-mediated activation of the Ras/mitogen-activated protein kinase pathway controls interleukin 4 receptor function and type-2 helper T cell differentiation. Proc Natl Acad Sci USA. 1999;96:1024–1029.
   PubMed Web of Science ®Google Scholar
• Dong C, Davis RJ, Flavell R. MAP kinases in the immune response. Annu Rev Immunol. 2002;20:55–72.
   PubMed Web of Science ®Google Scholar
• Pernis AB, Rothman PB. JAK-STAT signaling in asthma. J Clin Invest. 2002;109:1279–1283.
   PubMed Web of Science ®Google Scholar
• Winston LA, Hunter T. Intracellular signalling: putting JAKs on the kinase MAP. Curr Biol. 1996;6:668–671.
   PubMed Web of Science ®Google Scholar
• Basaki Y, Ikizawa K, Kajiwara K, et al. CD40-mediated tumor necrosis factor receptor-associated factor 3 signaling upregulates IL-4-induced germline Cε transcription in a human B cell line. Arch Biochem Biophys. 2002;405:199–204.
   PubMed Web of Science ®Google Scholar
• Bates ME, Green VL, Bertics PJ. ERK1 and ERK2 activation by chemotactic factors in human eosinophils is interleukin 5-dependent and contributes to leukotriene C4 biosynthesis. J Biol Chem. 2000;275:10968–10975.
   PubMed Web of Science ®Google Scholar
• Yamasaki S, Ishikawa E, Kohno M, et al. The quantity and duration of FcRgamma signals determine mast cell degranulation and survival. Blood. 2004;103:3093–3101.
   PubMed Web of Science ®Google Scholar
• Woo CH, Jeong DT, Yoon SB, et al. Eotaxin induces migration of RBL-2H3 mast cells via a Rac-ERK-dependent pathway. Biochem Biophys Res Comm. 2002;298:392–397.
   PubMed Web of Science ®Google Scholar
• Petecchia L, Sabatini F, Usai C, et al. Cytokines induce tight junction disassembly in airway cells via an EGFR-dependent MAPK/ERK1/2-pathway. Lab Invest. 2012;92:1140–1148.
   PubMed Web of Science ®Google Scholar
• Atherton HC, Jones G, Danahay H. IL-13-induced changes in the goblet cell density of human bronchial epithelial cell cultures: MAP kinase and phosphatidylinositol 3-kinase regulation. Am J Physiol Lung Cell Mol Physiol. 2003;285:L730–L739.
   PubMed Web of Science ®Google Scholar
• Boucherat O, Nadeau V, Bérubé-Simard FA, et al. Crucial requirement of ERK/MAPK signaling in respiratory tract development. Development. 2014;141:3197–3211.
   PubMed Web of Science ®Google Scholar
• Ustiyan V, Zhang Y, Perl AKT, et al. β-Catenin and Kras/Foxm1 signaling pathway are critical to restrict Sox9 in basal cells during pulmonary branching morphogenesis. Dev Dyn. 2016;245:590–604.
   PubMed Web of Science ®Google Scholar
• Lim JH, Kim HJ, Komatsu K, et al. Differential regulation of Streptococcus pneumonia-induced human MUC5AC mucin expression through distinct MAPK pathways. Am J Transl Res. 2009;1:300–311.
   PubMed Web of Science ®Google Scholar
• Gallelli L, Pelaia G, D’Agostino B, et al. Endothelin-1 induces proliferation of human lung fibroblasts and IL-11 secretion through an ETA receptor-dependent activation of MAP kinases. J Cell Biochem. 2005;96:858–868.
   PubMed Web of Science ®Google Scholar
• Gerthoffer WT, Singer CA. MAPK regulation of gene expression in airway smooth muscle. Respir Physiol Neurobiol. 2003;137:237–250.
   PubMed Web of Science ®Google Scholar
• Orsini MJ, Krymskaya VP, Eszterhas AJ, et al. MAPK superfamily activation in human airway smooth muscle: mitogenesis requires prolonged p42/p44 activation. Am J Physiol. 1999;277:L479–L488.
   PubMedGoogle Scholar
• Ramakrishnan M, Musa NL, Li J, et al. Catalytic activation of extracellular signal-regulated kinases induces cyclin D1 expression in primary tracheal myocytes. Am J Respir Cell Mol Biol. 1998;18:736–740.
   PubMed Web of Science ®Google Scholar
• Roth M, Zhao F, Zhong J, et al. Serum IgE induced airway smooth muscle cell remodeling is independent of allergens and is prevented by omalizumab. PLoS One. 2015;10:e0136549.
   PubMed Web of Science ®Google Scholar
• Duan W, Chan JH, Wong CH, et al. Anti-inflammatory effects of mitogen-activated protein kinase kinase inhibitor U0126 in an asthma mouse model. J Immunol. 2004;172:7053–7059.
   PubMed Web of Science ®Google Scholar
• Boehme SA, Sullivan SK, Crowe PD, et al. Activation of mitogen-activated protein kinase regulates eotaxin-induced eosinophil migration. J Immunol. 1999;163:1611–1618.
   PubMed Web of Science ®Google Scholar
• Tsang F, Koh AHM, Ting WL, et al. Effects of mitogen-activated protein kinase kinase inhibitor PD 098059 on antigen challenge of guinea-pig airways in vitro. Br J Pharmacol. 1998;125:61–68.
   PubMed Web of Science ®Google Scholar
• Bi M, Guo A, Zhao H, et al. Role of extracellular signal-regulated kinase 1/2 signaling pathway in the process of thrombin-promoting airway remodelling in ovalbumin-allergic rats. Immunopharmacol Immunotoxicol. 2015;37:26–34.
   PubMed Web of Science ®Google Scholar
• Pelaia G, Cuda G, Vatrella A, et al. Effects of hydrogen peroxide on MAPK activation, IL-8 production and cell viability in primary cultures of human bronchial epithelial cells. J Cell Biochem. 2004;93:142–152.
   PubMed Web of Science ®Google Scholar
• Chopra P, Kanoje V, Semwal A, et al. Therapeutic potential of inhaled p38 mitogen-activated protein kinase inhibitors for inflammatory pulmonary diseases. Curr Opin Invest Drugs. 2008;17:1411–1425.
   Google Scholar
• Kim C, Sano Y, Todorova K, et al. The kinase p38 alpha serves cell-type specific inflammatory functions in skin injury and coordinates pro- and anti-inflammatory gene expression. Nat Immunol. 2008;9:1019–1027.
   PubMed Web of Science ®Google Scholar
• Hammaker D, Firestein GS. “Go upstream, young man”: lessons learned from the p38 saga. Ann Rheum Dis. 2010;69:i77–i82.
   PubMed Web of Science ®Google Scholar
• Patel NR, Cunoosamy DM, Fageras M, et al. The development of AZD7624 for prevention of exacerbations in COPD: a randomized controlled trial. Int J Chron Obstruct Pulmon Dis. 2018;13:1019–1029.
   Web of Science ®Google Scholar
• Fisk M, Cheriyan J, Mohan D, et al. The p38 mitogen activated protein kinase inhibitor losmapimod in chronic obstructive pulmonary disease patients with systemic inflammation, stratified by fibrinogen: a randomised double-blind placebo-controlled trial. PLoS One. 2018;13:e0194197.
   PubMed Web of Science ®Google Scholar
• Gilfillan AM, Tkaczyk C. Integrated signalling pathways for mast-cell activation. Nat Rev Immunol. 2006;6:218–230.
   PubMed Web of Science ®Google Scholar
• Pelaia C, Calabrese C, Terracciano R, et al. Omalizumab, the first available antibody for biological treatment of asthma: more than a decade of real life effectiveness. Ther Adv Respir Dis. 2018;12:1753466618810192.
   Web of Science ®Google Scholar
• Pelaia C, Vatrella A, Busceti MT, et al. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab. Drug Des Devel Ther. 2017;11:3137–3144.
   PubMed Web of Science ®Google Scholar
• Pelaia G, Vatrella A, Busceti MT, et al. Role of biologics in severe eosinophilic asthma: focus on reslizumab. Ther Clin Risk Manag. 2016;12:1075–1082.
   PubMed Web of Science ®Google Scholar
• Pelaia C, Vatrella A, Bruni A, et al. Benralizumab in the treatment of severe asthma: design, development and potential place in therapy. Drug Des Devel Ther. 2018;21:619–628.
   Google Scholar
• Pelaia C, Calabrese C, Vatrella A, et al. Benralizumab: from the basic mechanism of action to the potential use in the biological therapy of severe eosinophilic asthma. Biomed Res Int. 2018:4839230.
   PubMed Web of Science ®Google Scholar
• Pelaia C, Vatrella A, Gallelli L, et al. Dupilumab for the treatment of asthma. Expert Opin Biol Ther. 2017;17:1565–1572.
   PubMed Web of Science ®Google Scholar
• Chupp GL, Kaur R, Mainardi A. New therapies for emefging endotypes of asthma. Annu Rev Med. 2020;71:25.1–25.14.
   PubMed Web of Science ®Google Scholar
• Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2020;55:1900588.
   PubMed Web of Science ®Google Scholar
• Pelaia G, Vatrella A, Maselli R. The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012;11:958–972.
   PubMed Web of Science ®Google Scholar
• Nakajima S, Kabata H, Kabashima K, et al. Anti-TSLP antibodies: targeting a master regulator of type 2 immune responses. Allergol Int. 2020. DOI:10.1016/j.alit.2020.01.001
   Google Scholar